Evidence and research literacy tool
Noah AI
Noah AI is a vendor-hosted, credit-metered research agent for the life sciences from TOLONGEVITY PTE. LTD. It plans multi-step research workflows, retrieves from PubMed, guidelines, trial registries, patents, and pharma databases, routes steps across GPT, Gemini, Claude, and Grok, and outputs cited reports and evidence tables. Unlike HCP-gated peers, it is public-facing: any patient can sign up and run cited evidence searches on a free tier. That access is undercut by a credit paywall, a professional register, a template privacy policy with ad-network sharing that never addresses research-query content, an explicit HIPAA exclusion, no medical-advice or clinical-boundary language anywhere in public terms or marketing, and an opaque company with no named leadership and no independent evaluation.
Public-source research has been drafted, often with AI assistance. No comprehensive human review is recorded unless the profile provenance says so.
Summary judgment · 55% toward patient-directed
Mixed
Noah gives any patient real, cited access to the same professional evidence base sold to pharma, investors, and clinicians, which can expand critical reflection. The posture stays mixed because the tool is designed, priced, and evaluated for industry, its largest patient effects flow invisibly through drug-program, launch, coverage, and investment decisions, and its legal architecture (HIPAA exclusion, no clinical boundary language, London/Cayman dispute stack, ad-tech data sharing) shifts risk onto the individual user.
Patient agency
How this tool changes agency
Health Search over NIH and FDA sources, cited PubMed synthesis, and evidence tables can support understanding and second-opinion preparation. Nothing is designed for patient action: no visit preparation, appeal support, record interpretation, or advocacy features, and the showcased workflows are industry actions.
Direct use is voluntary with a 300-credit free tier and an AI-processing opt-out of undefined scope in account settings. Sustained use requires non-refundable, auto-renewing annual fees of $148.80 to $1,999.20. Patients affected by industry- or clinician-mediated use have no choice and no notice.
Patient-facing signals
Who does this AI serve?
Designed, priced, and showcased for pharma, biotech, investors, consultants, and clinicians, with testimonials drawn entirely from industry users. Patients are one persona among many and can genuinely use the same retrieval infrastructure, but vendor and industry-customer interests dominate the embedded priorities.
Can patients tell AI is involved?
AI involvement is the explicit product identity, with a named model roster (GPT, Gemini, Claude, Grok) and a step-by-step agent workflow. Third parties affected by clinician or industry use of Noah outputs have no visibility, which is scored under choice and contestability.
Can patients meaningfully choose?
Direct use is voluntary with a 300-credit free tier and an AI-processing opt-out of undefined scope in account settings. Sustained use requires non-refundable, auto-renewing annual fees of $148.80 to $1,999.20. Patients affected by industry- or clinician-mediated use have no choice and no notice.
Can patients correct or challenge what the AI produces?
Citations on conclusions and downloadable underlying data make claims checkable, and a coverage check claims to flag conflicts and weak support. No structured error-reporting or correction workflow is documented, recourse is a support email, and patients affected by third-party use of Noah outputs have no challenge route at all.
Does it help patients understand or act?
Health Search over NIH and FDA sources, cited PubMed synthesis, and evidence tables can support understanding and second-opinion preparation. Nothing is designed for patient action: no visit preparation, appeal support, record interpretation, or advocacy features, and the showcased workflows are industry actions.
Text findings
Who is left out or burdened?
Credit-gated, professional-register tool that selects for already-advantaged users
Meaningful use costs about $41.60 per month on the recommended tier. Outputs are professional-grade reports with no disclosed plain-language, low-literacy, or accessibility support. Signup is 18+ only. The UI is multilingual but report-language support is not disclosed. The dispute stack (individual arbitration in London under Cayman substantive law, a $1,000 liability cap, no refunds) is effectively unusable for an individual patient.
What happens to patient data?
Template-grade policy with ad-tech sharing; query content and training use not disclosed
The privacy policy never addresses research queries or uploaded documents, the most sensitive data a patient would provide, and asserts "We do not process sensitive information." Queries route across four third-party LLM providers with no disclosed subprocessor or training-use terms. Sharing categories include Ad Networks, Retargeting Platforms, and Remarketing with Google Analytics. Services are hosted in Singapore, the terms are explicitly not HIPAA-tailored, and users whose interactions fall under HIPAA may not use the Services. Regional rights sections, account deletion, and an AI-processing opt-out exist.
Are the clinical boundaries clear?
Unclear
Despite marketing to doctors, medical students, and patients, neither the homepage nor the terms contains any not-medical-advice, consult-your-physician, escalation, or emergency language. The only disclaimer is generic AS-IS boilerplate, and the HIPAA exclusion functions as a liability shield rather than a safety boundary. In-product disclaimers behind the signup wall were not researched.
Who defined what good looks like?
Vendor-defined; no independent evidence found
All quality and anti-hallucination claims are vendor-stated, and social proof is four first-name-only industry testimonials. Searches this pass confirmed no published accuracy benchmark, peer-reviewed evaluation, independent audit, named leadership, or patient-partnered evaluation. The company's public footprint is limited to its two official domains, a LinkedIn page, and tool-directory listings.
Review provenance
Criteria
Same HugoScore CAIHL-derived criteria for every tool; public criteria are displayed from site/data/criteria.json, with fuller method notes in SCORING_FRAMEWORK.md.
Reviewer
AI-assisted public-source draft prepared in Claude (Cowork); no named human reviewer recorded.
AI / model
Claude Fable 5 (claude-fable-5), second-pass review. The 2026-08-12 first-pass draft was produced by a Claude Sonnet model per the project maintainer; its self-reported provenance misstated the model.
Human review
No comprehensive human review has been completed or claimed for this draft profile.
Review date
2026-08-13
Limitations
No account creation or product testing, no output-accuracy or citation-quality audit, no vendor or user interviews, no security or accessibility audit, no legal determination. Company-background claims limited to vendor documents plus searches confirming an absence of independent coverage.
Review method
Public-source review of the Noah AI homepage, pricing page, privacy policy, and terms of use, plus web searches for independent coverage and company background. Second-pass review re-verifying all first-pass claims. No account creation, product testing, output-accuracy or citation-quality audit, vendor or user interview, security audit, accessibility audit, independent validation, or legal determination.
Draft profile · Low-to-medium draft, official sources plus a confirmed absence of independent coverage